Cytochrome P450 2C9 genotyping-13654

Test info

Cytochrome P450 2C9 genotyping
DME genotyping

CYP2C9 is gene 9 within the C subfamily within the 2 family of the CYP450 superfamily. It metabolizes 5% of all prescribed drugs, such as glipizide, phenytoin, and warfarin. Genetic polymorphisms of CYP2C9 could be used to predict the altered enzyme activity and address the potential effects of metabolized drugs. Individuals exhibiting the most common variant alleles of 2C9, *2 or *3 are at increased risk of metabolizing a drug poorly or not at all. Deficient activity of 2C9 may result in reduced or lacking therapeutic benefit and an adverse drug reaction due to metabolite buildup in the body. This should be considered prior to initiating or modifying treatment or supplementing with additional drugs.


EDTA whole blood
4.0 mL
3.0 mL

Immediately following collection, mix sample thoroughly by gentle inverting 8 - 10 times, to prevent clotting


Lavender (EDTA), 4 mL

ACD whole blood

Yellow ACD (A or B)




Yellow ACD (A or B)


 Molecular Medicare billing request

  • Complete and submit the form to notify us of the need for Allina Health Laboratory to bill insurance for Molecular testing performed
  • All information requested is required in order for your request to be completed

Ambient (preferred) – 7 days

Refrigerated – 7 days

Frozen – 2 years

  • Hemolysis
  • Quantity not sufficient for analysis (QNS) 
  • Improper container


LabCorp RTP (511893): R-LC
1x/week, or as needed
6 - 10 days

Real time polymerase chain reaction (PCR)

Clinical and Interpretive info


An interpretive report will be provided


This test may require preauthorization from the insurance provider. Check the payer guidelines and, if needed, obtain the pre-authorization prior to sample collection.
Result 46724-1